^
Association details:
| Biomarker: | EGFR overexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | GC-1118A (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A first-in-human phase I study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with colorectal cancer and gastric/GEJ cancer
Published date:
10/09/2018
Excerpt:
Cohort 3 (C3) enrolled pts with EGFR over-expressing (2+,3+) metastatic GC cancer...In C3, PR was 8.33% (1/12), SD 16.67% (2/12), and PD 75.0%. The progression-free survival (PFS) were 14 weeks (95% CI: 7.1-30.1), 6.93 weeks (95% CI: 4.2-14.8), and 6.7 weeks (95% CI: 5.0-11.0), respectively...GC1118 showed promising anti-tumor activity...
DOI:
10.1093/annonc/mdy281.112
